Terms: = Lung cancer AND POLE, POLE1, 5426, FLJ21434, DKFZp434F222, ENSG00000177084
135 results:
1. SPC25 Functions as a Prognostic-Related Biomarker, and Its High Expression Correlates with Tumor Immune Infiltration and UCEC Progression.
Liao LX; Zhang M; Xu X; Zhang S; Guo YZ
Front Biosci (Landmark Ed); 2024 Feb; 29(2):69. PubMed ID: 38420826
[TBL] [Abstract] [Full Text] [Related]
2. Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
Dupain C; Gutman T; Girard E; Kamoun C; Marret G; Castel-Ajgal Z; Sablin MP; Neuzillet C; Borcoman E; Hescot S; Callens C; Trabelsi-Grati O; Melaabi S; Vibert R; Antonio S; Franck C; Galut M; Guillou I; Halladjian M; Allory Y; Cyrta J; Romejon J; Frouin E; Stoppa-Lyonnet D; Wong J; Le Tourneau C; Bièche I; Servant N; Kamal M; Masliah-Planchon J
BMC Biol; 2024 Feb; 22(1):43. PubMed ID: 38378561
[TBL] [Abstract] [Full Text] [Related]
3. SPC25 as a novel therapeutic and prognostic biomarker and its association with glycolysis, ferroptosis and ceRNA in lung adenocarcinoma.
Liu XS; Zhang Y; Ming X; Hu J; Chen XL; Wang YL; Zhang YH; Gao Y; Pei ZJ
Aging (Albany NY); 2024 Jan; 16(1):779-798. PubMed ID: 38217547
[TBL] [Abstract] [Full Text] [Related]
4. Comparison of gene mutation profile in different lung adenocarcinoma subtypes by targeted next-generation sequencing.
Zhang S; Dong P; Pan Z; Chen Q; Zhu J; Mao Z
Med Oncol; 2023 Nov; 40(12):349. PubMed ID: 37935925
[TBL] [Abstract] [Full Text] [Related]
5. Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.
Zhu M; Kim J; Deng Q; Ricciuti B; Alessi JV; Eglenen-Polat B; Bender ME; Huang HC; Kowash RR; Cuevas I; Bennett ZT; Gao J; Minna JD; Castrillon DH; Awad MM; Xu L; Akbay EA
Cancer Cell; 2023 Oct; 41(10):1731-1748.e8. PubMed ID: 37774698
[TBL] [Abstract] [Full Text] [Related]
6. Endometrial adenocarcinoma recurring in the lung: impact of molecular profile and role of local therapies on prognosis.
Luzarraga Aznar A; Bebia V; López-Gil C; Giraldo A; Montoya MP; Verges R; Jauregui A; Castellvi J; Pérez-Benavente A; Colás E; Gil-Moreno A; Cabrera S
Int J Gynecol Cancer; 2023 Oct; 33(10):1564-1571. PubMed ID: 37726197
[TBL] [Abstract] [Full Text] [Related]
7. Integrating pole/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer.
Zheng S; Cao Y; Randall J; Yu H; Thomas TO
Thorac Cancer; 2023 Aug; 14(23):2269-2274. PubMed ID: 37345618
[TBL] [Abstract] [Full Text] [Related]
8. Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms.
Riechelmann RP; Donadio MDS; Jesus VHF; de Carvalho NA; Santiago KM; Barros MJ; Lopes L; Oliveira Dos Santos G; Nirvana Formiga M; Carraro DM; Torrezan GT
Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36947458
[TBL] [Abstract] [Full Text] [Related]
9. [DIAGNOSIS OF GENETIC VARIANT CARRIERS IN A PATIENT WITH ASYMPTOMATIC BIRT-HOGG-DUBÉ SYNDROME: A CASE REPORT].
Watari S; Ichikawa T; Hirasawa A; Shiraishi H; Tokunaga M; Kubota R; Kusumi N; Tsushima T; Shinno Y; Furuya M
Nihon Hinyokika Gakkai Zasshi; 2023; 114(2):61-65. PubMed ID: 38644188
[TBL] [Abstract] [Full Text] [Related]
10. Brain metastases from small cell lung cancer and non-small cell lung cancer: comparison of spatial distribution and identification of metastatic risk regions.
Shi W; Wang Y; Xia W; Liu B; Ni M; Shen J; Bai Y; Weng G; Liu W; Yuan S; Gao X
J Neurooncol; 2023 Jan; 161(1):97-105. PubMed ID: 36520380
[TBL] [Abstract] [Full Text] [Related]
11. Multimodal evaluation of osteosarcoma choroidal metastasis.
Fernández Mancebo FM; Inga ME; Daich Varela M
Eur J Ophthalmol; 2023 Sep; 33(5):NP137-NP139. PubMed ID: 36062609
[TBL] [Abstract] [Full Text] [Related]
12. Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes.
Kumar S U; Balasundaram A; Cathryn R H; Varghese RP; R S; R G; Younes S; Zayed H; Doss C GP
Comput Biol Med; 2022 Sep; 148():105701. PubMed ID: 35753820
[TBL] [Abstract] [Full Text] [Related]
13. Isolated soft tissue mass of the finger as the first presentation of oligometastatic renal cell carcinoma.
Hopkins DT; Waters D; Manecksha RP; Lynch TH
BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35580945
[TBL] [Abstract] [Full Text] [Related]
14. DNA repair and immune checkpoint blockade response.
Guo JA; Alshalalfa M; Kim DY; Hoffman HI; Shiau C; Su J; Hwang WL; Mahal BA
Cancer Genet; 2022 Jun; 264-265():1-4. PubMed ID: 35245846
[TBL] [Abstract] [Full Text] [Related]
15. The Current and Evolving Role of Immunotherapy in Metastatic Colorectal cancer.
Silva VS; Riechelmann RP; Mello CA; Felismino T; Taboada R
Curr Cancer Drug Targets; 2022 Aug; 22(8):617-628. PubMed ID: 35209820
[TBL] [Abstract] [Full Text] [Related]
16. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.
Hwang GE; Lee JW; Jeon S; Cho IH; Kim HD
Doc Ophthalmol; 2022 Apr; 144(2):153-162. PubMed ID: 34997406
[TBL] [Abstract] [Full Text] [Related]
17. [Successful Re-Administration of Nivolumab in Patient with Metastatic Renal Cell Carcinoma : A Case Report].
Sasagawa H; Numakura K; Nakamura G; Kukimoto T; Kikuchi A; Sagehashi R; Yamamoto R; Koizumi A; Nara T; Kanda S; Saito M; Narita S; Inoue T; Satoh S; Habuchi T
Hinyokika Kiyo; 2021 Dec; 67(12):525-528. PubMed ID: 34991292
[TBL] [Abstract] [Full Text] [Related]
18. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer.
Du F; Liu Y
J Clin Lab Anal; 2022 Jan; 36(1):e24141. PubMed ID: 34817097
[TBL] [Abstract] [Full Text] [Related]
19. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.
Ramdani HO; Falk M; Heukamp LC; Schatz S; Tiemann M; Wesseler C; Diehl L; Schuuring E; Groen HJM; Griesinger F
Pathol Res Pract; 2021 Nov; 227():153651. PubMed ID: 34673351
[TBL] [Abstract] [Full Text] [Related]
20. Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting pole mutation and deficient mismatch repair pathway.
Vauchier C; Pluvy J; Theou-Anton N; Soussi G; Poté N; Brosseau S; Gounant V; Zalcman G
Lung Cancer; 2021 Oct; 160():28-31. PubMed ID: 34371300
[TBL] [Abstract] [Full Text] [Related]
[Next]
